替加环素鞘内注射治疗泛耐药鲍曼不动杆菌颅内感染1例报告及文献复习
|
摘要
1例患者经鼻行视神经减压术后发生泛耐药鲍曼不动杆菌颅内感染,给予静脉联合鞘内注射替加环素治疗,综合分析近五年相关文献,最终确定治疗方案。给予患者替加环素(首次100 mg,后续50 mg,q12h),联合头孢哌酮钠舒巴坦钠(3.0g,q8h)静脉滴注;替加环素2.5 mg,配伍5 mL生理盐水,q12h,腰大池引流管鞘内注射,夹闭2 h。鞘内注射替加环素15 d后患者连续4次脑脊液常规检查在正常范围,培养阴性,最终治愈。
One patient developed intracranial infection caused by extensively drug-resistant(XDR) Acinetobacter baumannii after intranasal endoscopic optic nerve decompression,intravenous combined intrathecal injection of tigecycline was given,treatment plan was finally determined through comprehensive analysis on relevant literatures in the past five years.Patient received intravenous drip of tigecycline(100 mg initially,followed by50 mg,q12h) combined with cefoperazone sodium/sulbactam sodium(3.0 g,q8h);intrathecal injection of tigecycline 2.5 mg combined with 5 mL saline,q12h through lumbar cisterna drainage tube,clipping for 2 hours.After intrathecal injection of tigecycline for 15 days,four consecutive routine cerebrospinal fluid examination of patients were all within the normal limits,the culture result was negative,patient was finally cured.
One patient developed intracranial infection caused by extensively drug-resistant(XDR) Acinetobacter baumannii after intranasal endoscopic optic nerve decompression,intravenous combined intrathecal injection of tigecycline was given,treatment plan was finally determined through comprehensive analysis on relevant literatures in the past five years.Patient received intravenous drip of tigecycline(100 mg initially,followed by50 mg,q12h) combined with cefoperazone sodium/sulbactam sodium(3.0 g,q8h);intrathecal injection of tigecycline 2.5 mg combined with 5 mL saline,q12h through lumbar cisterna drainage tube,clipping for 2 hours.After intrathecal injection of tigecycline for 15 days,four consecutive routine cerebrospinal fluid examination of patients were all within the normal limits,the culture result was negative,patient was finally cured.
引文
[1]Gaynes R,Edwards JR.Overview of nosocomial infections caused by gram-negative bacilli[J].Clin Infect Dis,2005,41(6):848-854.
[2]Krol V,Hamid NS,Cunha BA.Neurosurgically related nosocomial Acinetobacter baumannii meningitis:report of two cases and literature review[J].J Hosp Infect,2009,71(2):176-180.
[3]Tutuncu EE,Kuscu F,Gurbuz Y,et al.Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis[J].Int J Infect Dis,2010,14(Suppl 3):e224-e226.
[4]Cascio A,Mezzatesta ML,Odierna A,et al.Extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter cloacae ventriculitis successfully treated with intraventricular colistin[J].Int J Infect Dis,2014,20:66-67.
[5]潘志国,苏磊.成功救治泛耐药鲍曼不动杆菌致颅内感染1例[J].感染、炎症、修复,2014,15(1):54-55.
[6]Lauretti L,D’Alessandris QG,Fantoni M,et al.First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii[J].J Neurosurg,2017,127(2):370-373.
[7]Regaieg K,Bahloul M,Turki O,et al.The efficacy of the tigecycline-colistin association in the treatment of multi-resistant Acinetobacter baumannii meningitis[J].Med Mal Infect,2017,47(2):175-177.
[8]Simfukwe K,Zhou Y,Han G,et al.Management of intracranial ventriculitis caused by multidrug resistant Acinetobacter baumannii:case report and literature review[J].Med J Zambia,2017,44(1):58-63.
[9]Fang YQ,Zhan RC,Jia W,et al.A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii[J].Medicine(Baltimore),2017,96(31):e7703.
[10]赵健,王仙,张双,等.开颅术后并发泛耐药鲍曼不动杆菌性颅内感染病例报告并文献复习[J].临床神经外科杂志,2017,14(4):310-312.
[11]Wu Y,Chen K,Zhao J,et al.Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy:a case report[J].J Chemother,2018,30(1):49-52.
[12]缪应纯,徐晓林,缪应举,等.鲍曼不动杆菌研究进展[J].山东化工,2017,46(23):49-51.
[13]Brigante G,Migliavacca R,Bramati S,et al.Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNAmethylase ArmA[J].J Med Microbiol,2012,61(Pt 5):653-661.
[14]Pogue JM,Mann T,Barber KE,et al.Carbapenem-resistant Acinetobacter baumannii:epidemiology,surveillance and management[J].Expert Rev Anti Infect Ther,2013,11(4):383-393.
[15]Tafelski S,Wagner L,Angermair S,et al.Therapeutic drug monitoring for colistin therapy in severe multi-resistant Acinetobacterintracerebral abscess:A single case study with highdose colistin and review of literature[J].SAGE Open Med Case Rep,2017,5:2050313X17711630.
[16]Yi爧R.Evaluation of blood cultures in a children’s hospital located in Southeastern Anatolia[J].Turk Pediatri Ars,2015,50(2):102-107.
[17]Jawad A,Seifert H,Snelling AM,et al.Survival of Acinetobacter baumannii on dry surfaces:comparison of outbreak and sporadic isolates[J].J Clin Microbiol,1998,36(7):1938-1941.
[18]陈佰义,何礼贤,胡必杰.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85.
[19]Rodvold KA,Gotfried MH,Cwik M,et al.Serum,tissue and body fluid concentrations of tigecycline after a single 100 mg dose[J].J Antimicrob Chemother,2006,58(6):1221-1229.
[20]黎金海,陈嘉伟,郭旭光.替加环素联合舒巴坦对泛耐药鲍曼不动杆菌体外抗菌活性研究[J].今日药学,2016,26(7):482-488.
[21]苏小妹,邱前辉,詹建东,等.鼻内镜下视神经减压术治疗外伤性视神经损伤临床观察[J].中国耳鼻咽喉颅底外科杂志,2017,23(4):323-327.
[22]Cunha BA.Pharmacokinetic considerations regarding tigecycline for multidrug-resistant(MDR)Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis[J].J Clin Microbiol,2009,47(5):1613.
[23]Pankey GA.Tigecycline[J].J Antimicrob Chemother,2005,56(3):470-480.
[24]刘峰,邓贵新,刘锐锋.21例替加环素致药品不良反应[J].中国医院用药评价与分析,2018,18(7):1000-1004.
[25]严建泉,钱东翔,罗鹏,等.万古霉素微量泵控制持续鞘内注射治疗颅内感染[J].实用临床医药杂志,2014,18(7):91-93.
[2]Krol V,Hamid NS,Cunha BA.Neurosurgically related nosocomial Acinetobacter baumannii meningitis:report of two cases and literature review[J].J Hosp Infect,2009,71(2):176-180.
[3]Tutuncu EE,Kuscu F,Gurbuz Y,et al.Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis[J].Int J Infect Dis,2010,14(Suppl 3):e224-e226.
[4]Cascio A,Mezzatesta ML,Odierna A,et al.Extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter cloacae ventriculitis successfully treated with intraventricular colistin[J].Int J Infect Dis,2014,20:66-67.
[5]潘志国,苏磊.成功救治泛耐药鲍曼不动杆菌致颅内感染1例[J].感染、炎症、修复,2014,15(1):54-55.
[6]Lauretti L,D’Alessandris QG,Fantoni M,et al.First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii[J].J Neurosurg,2017,127(2):370-373.
[7]Regaieg K,Bahloul M,Turki O,et al.The efficacy of the tigecycline-colistin association in the treatment of multi-resistant Acinetobacter baumannii meningitis[J].Med Mal Infect,2017,47(2):175-177.
[8]Simfukwe K,Zhou Y,Han G,et al.Management of intracranial ventriculitis caused by multidrug resistant Acinetobacter baumannii:case report and literature review[J].Med J Zambia,2017,44(1):58-63.
[9]Fang YQ,Zhan RC,Jia W,et al.A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii[J].Medicine(Baltimore),2017,96(31):e7703.
[10]赵健,王仙,张双,等.开颅术后并发泛耐药鲍曼不动杆菌性颅内感染病例报告并文献复习[J].临床神经外科杂志,2017,14(4):310-312.
[11]Wu Y,Chen K,Zhao J,et al.Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy:a case report[J].J Chemother,2018,30(1):49-52.
[12]缪应纯,徐晓林,缪应举,等.鲍曼不动杆菌研究进展[J].山东化工,2017,46(23):49-51.
[13]Brigante G,Migliavacca R,Bramati S,et al.Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNAmethylase ArmA[J].J Med Microbiol,2012,61(Pt 5):653-661.
[14]Pogue JM,Mann T,Barber KE,et al.Carbapenem-resistant Acinetobacter baumannii:epidemiology,surveillance and management[J].Expert Rev Anti Infect Ther,2013,11(4):383-393.
[15]Tafelski S,Wagner L,Angermair S,et al.Therapeutic drug monitoring for colistin therapy in severe multi-resistant Acinetobacterintracerebral abscess:A single case study with highdose colistin and review of literature[J].SAGE Open Med Case Rep,2017,5:2050313X17711630.
[16]Yi爧R.Evaluation of blood cultures in a children’s hospital located in Southeastern Anatolia[J].Turk Pediatri Ars,2015,50(2):102-107.
[17]Jawad A,Seifert H,Snelling AM,et al.Survival of Acinetobacter baumannii on dry surfaces:comparison of outbreak and sporadic isolates[J].J Clin Microbiol,1998,36(7):1938-1941.
[18]陈佰义,何礼贤,胡必杰.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85.
[19]Rodvold KA,Gotfried MH,Cwik M,et al.Serum,tissue and body fluid concentrations of tigecycline after a single 100 mg dose[J].J Antimicrob Chemother,2006,58(6):1221-1229.
[20]黎金海,陈嘉伟,郭旭光.替加环素联合舒巴坦对泛耐药鲍曼不动杆菌体外抗菌活性研究[J].今日药学,2016,26(7):482-488.
[21]苏小妹,邱前辉,詹建东,等.鼻内镜下视神经减压术治疗外伤性视神经损伤临床观察[J].中国耳鼻咽喉颅底外科杂志,2017,23(4):323-327.
[22]Cunha BA.Pharmacokinetic considerations regarding tigecycline for multidrug-resistant(MDR)Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis[J].J Clin Microbiol,2009,47(5):1613.
[23]Pankey GA.Tigecycline[J].J Antimicrob Chemother,2005,56(3):470-480.
[24]刘峰,邓贵新,刘锐锋.21例替加环素致药品不良反应[J].中国医院用药评价与分析,2018,18(7):1000-1004.
[25]严建泉,钱东翔,罗鹏,等.万古霉素微量泵控制持续鞘内注射治疗颅内感染[J].实用临床医药杂志,2014,18(7):91-93.